Pharma's Patient Centricity Report 2016 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Pharma's Patient Centricity" report to their offering.

Many in the industry agree that patient centricity is a business imperative, but it is unclear precisely what it means in business or organizational terms, and less clear still how to achieve it within the pharmaceutical industry. Patient centricity is not a function, but a mindset, a new way of doing R&D and of conceiving of therapeutic solutions.

There are multiple forces driving greater patient centricity. These include payers' focus on outcomes, the need for product differentiation, new digital technologies and data sources, advances in genomics and personalized medicines, and the empowered consumer. But there are as many hurdles, not least the lack of a roadmap as to how to be patient-centric, the lack of standards around patient-centric data and processes, regulatory uncertainties, disciplinary silos, and engrained attitudes clinging to traditional metrics and approaches to drug development.

This report addresses:

- Drivers and resistors of patient centricity

- Patient centricity in practice

- Patient centricity impact on organizations and cultures

- Selected case studies along the value chain

Key Topics Covered:

Executive Summary

1. Drivers and resistors of patient centricity

2. Patient centricity in practice

3. Patient centricity means changing organizations and cultures

4. Selected case studies along the value chain

Drivers and Resistors of Patient Centricity

5. Patient centricity is more mindset than process

6. Drivers and resistors

7. Drivers

8. Resistors

9. Bibliography

Patient Centricity in Practice

10. From discovery to commercialization

11. Bibliography

Patient Centricity Means Changing Organisations and Cultures

12. New ways of thinking

13. Changing the language

14. Top-down and bottom-up leadership

15. Lessons from other industries

16. Technology enables patient centricity and demands new treatment paradigm

17. Focus on outcomes, business will follow

18. Patient centricity playbooks are emerging

19. Bibliography

Selected Case Studies Along the Value Chain

20. UCB: re-organizing around patients

21. Sanofi: diffusing patient-centric innovation

22. LEO Pharma: leading the pack in patient centricity

23. Actelion: new approaches to patient-relevant trial measures

24. AstraZeneca: engaging patients in research

25. Novo Nordisk: a patient-centric heritage

26. Shire: spreading patient centricity beyond rare diseases

27. Bibliography

For more information visit http://www.researchandmarkets.com/research/mhxwd5/pharmas_patient

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals